What is the recommended interval between the first and second doses of Bexsero (meningococcal group B vaccine) for a 2‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bexsero Dosing Interval for 2-Year-Olds

For a 2-year-old child, the interval between the first and second doses of Bexsero is 6 months (0 and 6 months schedule). 1

FDA-Approved Dosing Schedule

The FDA label for Bexsero specifies two dosing options 1:

  • Two-dose schedule: Administer doses at 0 and 6 months
  • Three-dose schedule: Administer doses at 0,1-2, and 6 months

If the second dose is given earlier than 6 months after the first dose, a third dose must be administered at least 4 months after the second dose. 1

Important Context and Caveats

Age Limitation

Bexsero is FDA-approved only for individuals aged 10-25 years 1. Use in a 2-year-old is considered off-label 2. The ACIP guidelines do not provide specific recommendations for routine MenB vaccination in 2-year-olds unless they have specific risk factors.

Risk-Based Considerations

The choice between the 2-dose and 3-dose schedule depends on:

  • The individual's risk of exposure to meningococcal disease
  • The child's susceptibility to meningococcal serogroup B disease 1

For children at increased risk (e.g., complement deficiency, asplenia, HIV infection), the 3-dose schedule may be more appropriate to ensure optimal protection.

Recent Updates (October 2024)

The FDA recently updated the Bexsero label to extend the interval from ≥1 month to 6 months between doses, based on new immunogenicity data showing improved antibody responses with the longer interval 3. This change aligns Bexsero dosing with the other licensed MenB vaccine (Trumenba).

Clinical Pitfall

Do not interchange Bexsero with other meningococcal group B vaccines to complete the vaccination series, as there are insufficient data on safety and effectiveness of interchangeability 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.